Merck and AstraZeneca have seen their share prices surge after Bristol-Myers Squibb suffered a major setback with Opdivo in non-small cell lung cancer (NSCLC). BMS announced on Friday that Opdivo ...

Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient death in a ...

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma. Among patients with ...

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced the risk of disease progression or death by 38% in a Phase 3 trial for ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy. Among patients with resectable non-small cell ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal antibody Yervoy (ipilimumab ...

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced ...

Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on ...